zoledronic acid has been researched along with Adenocarcinoma, Basal Cell in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 29 (49.15) | 29.6817 |
| 2010's | 29 (49.15) | 24.3611 |
| 2020's | 1 (1.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bitzer, M; Lordick, F; Maurus, D; Sahin, U; Thuss-Patience, P; Türeci, Ö | 1 |
| Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H | 1 |
| Bahleda, R; Escudier, B; Gueutin, V; Izzedine, H; Rouvier, P; Soria, JC; Varga, A | 1 |
| Bhoopalam, N; Halabi, S; Hauke, RJ; Hussain, A; Kelly, WK; Monk, JP; Morris, M; Ryan, CJ; Saad, F; Sanford, B; Saylor, P; Small, EJ; Smith, MR; Stadler, W; Vogelzang, N | 1 |
| da Silva, DP; de Almeida, FC; de Araujo, ME; Marcucci, M; Marques, MM; Moreira, MS | 1 |
| Bouvet, M; Hayashi, K; Hiroshima, Y; Hoffman, RM; Kimura, H; Matsumoto, Y; Miwa, S; Sugimoto, N; Tsuchiya, H; Uehara, F; Yamamoto, M; Yamamoto, N; Yano, S; Zhang, Y | 1 |
| Baine, MJ; Batra, SK; Chen, S; Gupta, S; Jain, M; Johansson, SL; Kaur, S; Lazenby, A; Lester, K; Lin, C; Rachagani, S; Smith, L; Souchek, JJ; Zheng, D | 1 |
| Saad, F | 1 |
| Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Diamond, T; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; Oldmeadow, C; Spry, NA; Steigler, A; Tai, KH; Turner, S | 1 |
| Cappetta, A; Evangelista, L; Opocher, G; Pastorelli, D; Spano, L; Zovato, S | 1 |
| Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| Gehi, D; Rubin, CD; Tachibana, I | 1 |
| Atkinson, C; Attia, J; Christie, D; Delahunt, B; Denham, JW; Duchesne, G; Egevad, L; Joseph, D; Matthews, J; Murray, JD; Spry, NA; Srigley, JR; Steigler, A | 1 |
| Joensuu, TK | 1 |
| Kressley, A; Saif, MW; Smith, A | 1 |
| Gupta, NP; Nayyar, R; Sharma, N | 1 |
| Yuasa, T | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nishioka, Y; Ogino, H; Otsuka, S; Sone, S; Takahashi, T; Yamada, T; Yano, S | 1 |
| Bornstein, MM; Frei, M; Iizuka, T; Reichart, PA; Schaller, B; Weimann, R | 1 |
| Boudjema, K; Bouet-Toussaint, F; Cabillic, F; Catros, V; Daniel, P; de La Pintière, CT; Lavoué, V; Mönkkönen, H; Mönkkönen, J; Rioux-Leclerc, N; Toutirais, O; Turlin, B | 1 |
| Hering, F; Meler, A; Rodrigues, P | 1 |
| Chang, HJ; Chang, JW; Li, YY; Liu, YC; Su, SP; Tsai, MC; Wang, CH; Yeh, KY | 1 |
| Fujii, N; Ito, H; Nakabayashi, M; Ryoke, K; Shomori, K; Tamura, T | 1 |
| Kakehi, Y; Kato, T; Kazuki, N; Kushida, Y; Kuwata, Y; Matsuoka, Y; Taoka, T; Yamamoto, N | 1 |
| Fujitaka, K; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Murai, H; Nagao, S; Ohshimo, S | 1 |
| Culine, S; Pouessel, D | 1 |
| Belt, BA; Gillanders, WE; Goedegebuure, P; Herndon, J; Hsieh, CS; Lee, HM; Linehan, DC; Mitchem, JB; Porembka, MR | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M | 1 |
| Abdelkarim, M; Crepin, M; Di Benedetto, M; Jais, JP; Kassis, N; Lecouvey, M; Perret, GY; Vintonenko, N | 1 |
| Nguyen, PL | 1 |
| Atkinson, C; Christie, D; Delahunt, B; Denham, JW; Duchesne, G; Gogna, NK; Joseph, D; Kenny, L; Lamb, DS; Matthews, J; McElduff, P; Spry, NA; Tai, KH; Turner, S; Wilcox, C | 1 |
| Balakumaran, A; Ciuleanu, TE; García-Sáenz, JA; Henry, DH; Hirsh, V; Jacobs, I; Kanarev, V; Krzakowski, M; Lipton, L; Manegold, C; Mehta, ND; Pereira, JR; Prabhash, K; Rodriguez, G; Scagliotti, GV; Siena, S; Solal-Celigny, P; Wang, H; Woll, PJ | 1 |
| Dohdoh, M; Endo, Y; Kuroishi, T; Nagai, Y; Ohki, A; Oizumi, T; Sugawara, S; Tanaka, Y | 1 |
| Gomez-Veiga, F; Martinez-Breijo, S; Morote, J; Planas, J; Ponce-Reixa, J | 1 |
| Datta, HK; Hanusch, B; Tuck, SP; Walker, J | 1 |
| Davies, M; Gates, J; Jo, M; Lee, YP; Lieberman, JR; Schwarz, EM; Wu, J; Zhang, X | 1 |
| Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ | 1 |
| Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M | 1 |
| Altundag, K; Altundag, O; Gunduz, M; Morandi, P | 2 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Brahmbhatt, V; Patel, K; Ramu, V | 1 |
| Altun, B; Altundag, K; Elkiran, T; Gullu, I; Kurt, M; Onal, IK | 1 |
| Hellie, CM; Olson, KB; Pienta, KJ | 1 |
| Cormio, G; Cuccovillo, A; Fattizzi, N; Loizzi, V; Selvaggi, L | 1 |
| Katsouda, E; Mystakidou, K; Parpa, E; Vlahos, L | 1 |
| Bishop, PA; Hay, KD | 1 |
| Beer, TM; Demers, LM; Huo, D; Lacerna, LV; Ryan, CW | 1 |
| Doyle-Lindrud, S | 1 |
| Abbruzzese, A; Baldi, A; Bertieri, R; Budillon, A; Caraglia, M; D'Alessandro, AM; Leonetti, C; Marra, M; Meo, G; Santini, D; Tonini, G; Zupi, G | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G | 1 |
| Duivenvoorden, WC; Kalina, M; Seidlitz, E; Singh, G; Vukmirović-Popović, S | 1 |
| Afonso, Y; Bruna, P; Hering, FO; Meller, A; Rodrigues, P | 1 |
| Bylow, K; Demers, LM; Henderson, TO; Huo, D; Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Bellomi, M; Bruschini, R; Cossu Rocca, M; Goldhirsch, A; Nole, F; Preda, L; Sanna, G; Verri, E | 1 |
| Aguilera Tubet, C; Ballestero Diego, R; Roca Edreira, A; Villanueva Peña, A; Zubillaga Guerrero, S | 1 |
| Arlen, PM; Dahut, WL; Gulley, JL; Wu, S | 1 |
| Fernandez, SA; Martin, CK; Nadella, MV; Pinzone, JJ; Rosol, TJ; Thudi, NK; Werbeck, JL | 1 |
5 review(s) available for zoledronic acid and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Double-Blind Method; Forecasting; Fractures, Spontaneous; Humans; Imidazoles; Male; Models, Biological; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Practice Guidelines as Topic; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2013 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid | 2002 |
Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid.
Topics: Adenocarcinoma; Androgen Antagonists; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid | 2005 |
Two cases of endometrial cancer diagnosis associated with bone metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cervical Vertebrae; Cyclophosphamide; Diphosphonates; Doxorubicin; Endometrial Neoplasms; Fatal Outcome; Female; Humans; Imidazoles; Middle Aged; Platinum; Spinal Neoplasms; Tibia; Zoledronic Acid | 2006 |
Implications of androgen-deprivation therapy in patients with prostate cancer: A case study.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Jaw Diseases; Leuprolide; Male; Orchiectomy; Osteonecrosis; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, Conformal; Risk Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
14 trial(s) available for zoledronic acid and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Claudins; Esophagogastric Junction; Humans; Interleukin-2; Stomach Neoplasms; Zoledronic Acid | 2023 |
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Imaging; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2014 |
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2014 |
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid | 2015 |
Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Antineoplastic Agents; Biopsy, Large-Core Needle; Chemoradiotherapy; Consensus Development Conferences as Topic; Diphosphonates; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Pathology, Surgical; Proportional Hazards Models; Prostatic Neoplasms; Societies, Medical; Urology; Zoledronic Acid | 2015 |
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study.
Topics: Absorptiometry, Photon; Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Brazil; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Neoplasm Recurrence, Local; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid | 2010 |
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Brachytherapy; Diphosphonates; Humans; Imidazoles; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Quality of Life; Radiotherapy Dosage; Zoledronic Acid | 2012 |
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Denosumab; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; RANK Ligand; Small Cell Lung Carcinoma; Survival Rate; Young Adult; Zoledronic Acid | 2012 |
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2002 |
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Time Factors; Zoledronic Acid | 2006 |
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Osteoporosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Double-Blind Method; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Orchiectomy; Osteoporosis; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2007 |
40 other study(ies) available for zoledronic acid and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2018 |
Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Carcinoma, Renal Cell; Cisplatin; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Glutamates; Guanine; Humans; Imidazoles; Indoles; Interferons; Kidney Tubules; Lung Neoplasms; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Middle Aged; Necrosis; Nephrectomy; Pemetrexed; Prednisone; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases; Vincristine; Zoledronic Acid | 2013 |
New uses for rehabilitation protocol for oral sinus communications in ARONJ patients.
Topics: Adenocarcinoma; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clinical Protocols; Dental Prosthesis Design; Denture Design; Denture, Complete, Upper; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Jaw, Edentulous; Male; Maxilla; Neoadjuvant Therapy; Oroantral Fistula; Palatal Obturators; Patient Care Planning; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Fluorescence-guided surgery of prostate cancer bone metastasis.
Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease-Free Survival; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Lymphatic Metastasis; Male; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm, Residual; Optical Imaging; Prostatic Neoplasms; Red Fluorescent Protein; Zoledronic Acid | 2014 |
Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cholesterol; Diphosphonates; DNA, Complementary; Gene Expression Profiling; Gene Knockdown Techniques; Geranyltranstransferase; Humans; Imidazoles; Immunohistochemistry; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Zoledronic Acid | 2014 |
Role of bisphosphonates in non-metastatic prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Brachytherapy; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Middle Aged; Positron-Emission Tomography; Stomach Neoplasms; Treatment Outcome; Zoledronic Acid | 2015 |
Treatment of Hypertrophic Osteoarthropathy With Underlying Pulmonary Adenocarcinoma Using Zoledronic Acid.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Analgesics, Opioid; Bone Density Conservation Agents; Diphosphonates; Glucocorticoids; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Osteoarthropathy, Secondary Hypertrophic; Pain Management; Pain Measurement; Pneumonectomy; Treatment Outcome; Zoledronic Acid | 2015 |
Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2008 |
Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Neoplasm Staging; Osteonecrosis; Pancreatic Neoplasms; Zoledronic Acid | 2009 |
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
A bone metastasis model with osteolytic and osteoblastic properties of human lung cancer ACC-LC-319/bone2 in natural killer cell-depleted severe combined immunodeficient mice.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Endothelin-1; Humans; Imidazoles; Killer Cells, Natural; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Mice, SCID; Osteoblasts; Osteolysis; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaw combined with jaw metastasis of prostate adenocarcinoma: report of a case.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2010 |
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Topics: Adenocarcinoma; Aged; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Hepatocellular; Cell Differentiation; Cell Proliferation; Coculture Techniques; Colorectal Neoplasms; Cytotoxicity, Immunologic; Dendritic Cells; Diphosphates; Diphosphonates; Female; Flow Cytometry; Hemiterpenes; Humans; Imidazoles; Immunotherapy, Adoptive; Liver Neoplasms; Male; Middle Aged; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Zoledronic Acid | 2010 |
Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Diphosphonates; Diterpenes; Down-Regulation; E2F Transcription Factors; Imidazoles; Lung Neoplasms; Mevalonic Acid; Mice; Mice, Inbred BALB C; Phosphorylation; Protein Transport; ras Proteins; Retinoblastoma Protein; Zoledronic Acid | 2011 |
Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Caspases; Cell Cycle; Cell Proliferation; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Immunoenzyme Techniques; Mouth Neoplasms; Salivary Gland Neoplasms; Tumor Cells, Cultured; Zoledronic Acid | 2011 |
[Disseminated carcinomatosis of the bone marrow in two patients with prostate cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Bone Marrow Neoplasms; Carcinoma; Diphosphonates; Disseminated Intravascular Coagulation; Drug Therapy, Combination; Fatal Outcome; Humans; Imidazoles; Leuprolide; Male; Middle Aged; Nitriles; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome; Zoledronic Acid | 2011 |
Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Neoplasm Regression, Spontaneous; Zoledronic Acid | 2011 |
Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
Topics: Adenocarcinoma; Animals; Bone Marrow Cells; Cell Differentiation; Diphosphonates; Disease Models, Animal; Humans; Imidazoles; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Tumor Microenvironment; Up-Regulation; Zoledronic Acid | 2012 |
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid | 2012 |
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease Progression; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Transcriptome; Zoledronic Acid | 2012 |
Harms versus benefits with duration of androgen suppression.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Brachytherapy; Diphosphonates; Humans; Imidazoles; Leuprolide; Male; Prostatic Neoplasms; Quality of Life; Zoledronic Acid | 2012 |
In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells.
Topics: Adenocarcinoma; Annexin A5; Apoptosis; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cells, Cultured; Coloring Agents; Dental Cementum; Diphosphonates; Endothelial Cells; Endothelium, Vascular; Etidronic Acid; Fibroblasts; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Leukemia, Monocytic, Acute; Mesenchymal Stem Cells; Periodontal Ligament; Propidium; Tetrazolium Salts; Umbilical Veins; Zoledronic Acid | 2013 |
Prostate cancer and osteoporosis.
Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2013 |
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Hindlimb; Humans; Imidazoles; Male; Mice; Mice, SCID; Osteoblasts; Osteoclasts; Prostatic Neoplasms; Radiography; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2002 |
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Dexamethasone; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2004 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Diphosphonates; Humans; Imatinib Mesylate; Imidazoles; Male; Neoplasm Proteins; Palliative Care; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure; Zoledronic Acid | 2005 |
Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Pain; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma.
Topics: Acute Disease; Adenocarcinoma; Diphosphonates; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Tumor Lysis Syndrome; Zoledronic Acid | 2005 |
Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid.
Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2005 |
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Patient Care Planning; Tooth Extraction; Zoledronic Acid | 2006 |
R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinolones; ras Proteins; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxycycline; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Necrosis; Oral Fistula; Osteolysis; Osteomyelitis; Pamidronate; Prostatic Neoplasms; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
[Mediastinal lymph nodes during the course of a metastatic prostate cancer].
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyproterone; Diphosphonates; Estramustine; Fatal Outcome; Flutamide; Humans; Imidazoles; Ketoconazole; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Radionuclide Imaging; Skin Neoplasms; Triptorelin Pamoate; Zoledronic Acid | 2007 |
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Topics: Adenocarcinoma; Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Transformed; Diphosphonates; Disease Models, Animal; Dogs; Imidazoles; Incidence; Luminescent Proteins; Male; Mice; Mice, Nude; Osteoclasts; Osteolysis; Prostatic Neoplasms; Radiography; Zoledronic Acid | 2008 |